Cannabinoids Delay Huntington’s Disease Progression

  • According to experimental data published in The Journal of Neuroscience Research, the combined administration of the plant cannabinoids THC and CBD (cannabidiol) provide neuroprotection in rat models of Huntington’s disease (HD).

    Huntington’s disease is an inherited degenerative disorder of the brain that is characterized by motor abnormalities and dementia produced by selective lesions in the cerebral cortex. Presently, there are no known conventional therapies available for alleviating HD symptoms or delaying HD-associated striatal degeneration.

    An international team of investigators from Spain, Italy, and the United Kingdom assessed whether botanic extracts rich in THC and CBD can delay the progress of the disease in laboratory animals. Authors reported, “Our data demonstrates that a [one to one] combination of THC and CBD-enriched botanical extracts protected striatal neurons against … toxicity.” By contrast, the administration of individual, selective synthetic cannabinoid agonists did not produce similarly favorable outcomes.

    Investigators concluded, “In our opinion, these data provide sufficient preclinical evidence to justify a clinical evaluation of [one to one THC to CBD] cannabis-based medicine … as a neuroprotective agent capable of delaying disease progression in patients affected by HD, a disorder that is currently poorly managed in the clinic, prompting an urgent need for clinical trials with agents showing positive results in preclinical studies.”

    Reference:
    Neuroprotective effects of Phytocannabinoid-based medicines in experimental models of Huntington’s Disease-The Journal of Neuroscience Research

  • Tags: , , , , , ,
  • Comments